Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Authors:

Abstract
Malignant pleural mesothelioma (MPM) is considered to be a relatively rare tumour. In Great Britain, the incidence in males is 3.4/100 000, in France it is 2.3/100 000 and in the Netherlands it is 3.2/100 000. In the last 10 years, the incidence of MPM has increased slightly, mainly due to the lag time of 30–50 years after exposure to asbestos and the banning of handling and importing this product in the late twentieth century. The World Health Organisation (WHO) estimates asbestos-related disease (ARD) accounts for 92 250 deaths per year globally [1]. Occupational exposure to asbestos accounts for more than 80% of the cases and makes MPM a preventable disease. Although the Western world is moving towards a levelling-off of ARD incidence, the continued use of asbestos in the developing world could lead to a global epidemic of MPM. Even though asbestos is banned in Europe, other developed countries have only controlled the import, but not abolished handling of asbestos products. Recently, a germline mutation in the BAP1 gene has been linked to predisposition in some cases of MPM [2]. Somatic mutations may also play a role in the development of MPM.

This publication has 55 references indexed in Scilit: